Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections – SMART United States 2018–2019

BACKGROUND: Ceftolozane/tazobactam (C/T) is approved in 70 countries, including the United States, for the treatment of patients with hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible Gram-negative pathogens. C/T is of particular importance as an agent for the tre...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Microbiol
Auteurs principaux: Karlowsky, James A., Lob, Sibylle H., Young, Katherine, Motyl, Mary R., Sahm, Daniel F.
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2021
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7936229/
https://ncbi.nlm.nih.gov/pubmed/33676406
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12866-021-02135-z
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires